The challenge of compliance and persistence: Focus on ulcerative colitis

Journal of Managed Care Pharmacy

Volumn 14, Issue 1 SUPPL. A, 2008, Pages

  Kane, Sunanda V ^a   Brixner, Diana ^b,c   Rubin, David T ^d   Sewitch, Maida J ^e  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BALSALAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NIFEDIPINE; SALAZOSULFAPYRIDINE; STEROID;

ARTICLE; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CARCINOMA; COST BENEFIT ANALYSIS; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ENTERITIS; HEALTH CARE COST; HEALTH CARE DELIVERY; HELICOBACTER INFECTION; HIGH RISK BEHAVIOR; HUMAN; HYPERTENSION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT SAFETY; PRESCRIPTION; RECURRENCE RISK; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 39549091909     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.s1-a.1a     Document Type: Article

References (53)

1. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288:2868-79.
2. National Council on Patient Information and Education. Public policy & adherence. Available at: www.talkaboutrx.org/med_compliance.jsp. Accessed June 20, 2007.
3. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006; 296:2563-71.
4. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-50.
5. Hanauer S, Sninsky CA, Robinson M, et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med. 1996;124:204-11.
6. Miner P, Hanauer S, Robinson M, Schwartz J, Arora S. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci. 1995;40:296-30
7. Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001;96:2929-33.
8. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Available at: www.ispor.org/sigs/ MCP_accomplishments.asp#definition. Accessed June 4, 2007.
9. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006;23:577-85.
10. Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol. 1999;94:1733-42.
11. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97.
12. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449-57.
13. Lowry KP, Dudley TK, Oddone EZ, Bosworth HB. Intentional and unintentional nonadherence to antihypertensive medication. Ann Pharmacother. 2005;39:1198-1203.
14. Sewitch MJ, Leffondre K, Dobkin PL. Clustering patients according to health perceptions: relationships to psychosocial characteristics and medication nonadherence. J Psychosom Res. 2004;56:323-32.
15. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol. 2003; 98:1535-44.
16. Ockene IS, Hayman LL, Pasternak RC, Schron E, Dunbar-Jacob J. Task force #4 - adherence issues and behavior changes: achieving a long-term solution. 33rd Bethesda Conference. J Am Coll Cardiol. 2002;40:630-40.
17. Kane S. Adherence issues in management of inflammatory bowel disease. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Ontario: BC Decker; 2001:9-11.
18. Bedell SE, Jabbour S, Goldberg R, et al. Discrepancies in the use of medications: their extent and predictors in an outpatient practice. Arch Intern Med. 2000;160:2129-34.
19. Billups SJ, Malone DC, Carter BL. The relationship between drug therapy noncompliance and patient characteristics, health-related quality of life, and health care costs. Pharmacotherapy. 2000;20:941-49.
20. Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Editorial. Med Care. 2005,43:517-20.
21. Krousel-Wood M, Thomas S, Muntner P, Morisky D. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol. 2004; 19:357-62.
22. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut. 2007;56:1353-57.
23. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007;102:1417-26.
24. van Hees PAM, van Tongeren JHM. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol. 1982;4:333-36.
25. Rubin G, Hungin AP, Chinn D, Dwarakanath AD, Green L, Bates J. Long-term aminosalicylate therapy is under-used in patients with ulcerative colitis: a cross-sectional survey. Aliment Pharmacol Ther. 2002;16:1889-93.
26. Kane SV, Huo D, Aikens J, Hanauer SB. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39-43.
27. Kane SV, Aikens J, Hanauer SB. Medication regimens are associated with non-adherence in quiescent ulcerative colitis. Am J Gastroenterol. 2002;97:S253. Abstract 770.
28. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm. 2006;12:239-45.
29. van der Wal MH, Jaarsma T, van Veldhuisen DJ. Non-compliance in patients with heart failure; how can we manage it? Eur J Heart Fail. 2005;7:5-17.
30. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25:2958-71.
31. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol. 1996;98:1051-57.
32. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation. 1990;49:374-77.
33. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998; 55:1128-32.
34. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005,43:521-30.
35. Sewitch MJ, Blais R, Rahme E, Bexton B, Galarneau S. Receiving guideline-concordant pharmacotherapy for major depression: impact on ambulatory and inpatient health service use. Can J Psychiatry. 2007; 52:191-200.
36. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-ammosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005;100:1345-53.
37. Moody GA, Jayanthi V, Probert CSJ, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179-83.
38. Brixner D, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. Academy of Managed Care Pharmacy Annual Meeting. San Diego, CA; 2007.
39. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative Colitis. Clin Gastroenterol Hepatol. 2003;1:170-73.
40. Magowan S, Kane S, Lange JL. 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens. Am J Gastroenterol. 2006;101:S447. Abstract 1144.
41. Magowan SH, Accortt N, Brixner D. Prescription refill behavior for nifedipine therapy is significantly associated with medication cost. Circulation. 2007;115:11-12. Abstract 50.
42. Brixner DI, Joish VN, Odera GM, Avey SG, Hanson DM, Cannon HE. Effects of benefit design change across 5 disease states. Am J Manag Care. 2007;13:370-76.
43. Loftus EV Jr. A practical perspective on ulcerative colitis: patients' needs from ammosalicylate therapies. Inflamm Bowel Dis. 2006;12:1107-13.
44. Loftus EV Jr., Kane SV, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004;19:179-89.
45. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-85.
46. Remicade. Package insert. Centocor Inc.; Malvern, PA: December 2006.
47. Bernal I, Domenech E, Garcia-Planella E, et al. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig Dis Sci. 2006;51:2165-69.
48. Nigro G, Angelini G, Grosso SB, Caula G, Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol. 2001;32:66-68.
49. Kane S, Magowan S, Accortt N, Brixner D. Predictors of 5-ASA prescription persistence in patients with ulcerative colitis. Gastroenterology. 2007;132:A-347. Abstract M1033.
50. Adler DA, Bungay KM, Wilson IB, et al. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. Gen Hosp Psychiatry. 2004;26:199-209.
51. McCoy MR, Couch D, Duncan ND, Lynch GS. Evaluating an internet weight loss program for diabetes prevention. Health Promot Int. 2005;20:221-28.
52. Ralston JD, Revere D, Robins LS, Goldberg HI, Patients' experience with a diabetes support programme based on an interactive electronic medical record: qualitative study. BMJ. 2004;328:1159.
53. Fuhrmans V. New tack on copays: cutting them. Wall Street Journal. May 8, 2007. Available at: http://online.wsj.com/article/ SB117857848288195042.html. Accessed August 24, 2007.